The Desmoid Tumor Research Foundation is dedicated to spreading knowledge about desmoid tumors among clinicians and researchers.
We form partnerships with entities that specialize in creating authorized Continuing Medical Education (CME) credit courses for medical professionals, providing the opportunity and incentive to increase their understanding of this rare tumor type and its treatment.
These courses are available to medical oncologists, surgical oncologists, general surgeons, advanced practice clinicians, and other healthcare professionals involved in the care of patients with desmoid tumors to ensure the greatest potential impact on patient outcomes.
Current CME-certified programs on desmoid tumors:
Creators:
Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders (NORD) and the Desmoid Tumor Research Foundation (DTRF)
Availability:
Enduring Start: December 12, 2023 (no live component)
Program Expiration: December 12, 2024
Description:
Desmoid tumors are challenging to manage due to the difficulty obtaining an accurate diagnosis and the scarcity of treatment options. Despite the benefits seen with tyrosine kinase inhibitors, there are no FDA-approved therapies yet for treatment of desmoid tumors. However, emerging therapies are showing clinical benefit and have the potential to improve the treatment armamentarium.
Join a panel of experts to discuss the best strategies to improve timely diagnoses of patients with desmoid tumors. Experts will review the recent shift away from extensive surgery to active surveillance and explore emerging treatments that have demonstrated promising results for patients with progressive disease. Panelists will also discuss the need for multidisciplinary review to determine if treatment is warranted and examine which patients are eligible for treatment with emerging options.
Learning Objectives:
- Apply relevant strategies to address timely diagnosis in patients with desmoid tumors
- Discuss patient selection for treatment based on safety and efficacy data
Topics of Interest:
- Impact of misdiagnoses on outcomes with desmoid tumors
- Practical strategies to improve diagnostic accuracy
- Treatment burden and patient quality of life
- Conventional treatment approaches
- Gamma secretase inhibitors
- Where do emerging agents fit in the timeline?
- Role of the multidisciplinary team in care
- Special considerations for adolescent and young adult (AYA) patients
- Counseling patients about clinical trials, resources, and patient organizations
Top Faculty/ KOLs:
Mrinal Gounder, MD
Associate Attending Professor
Sarcoma Oncologist & Early Phase Drug Development Specialist
Memorial Sloan Kettering Cancer Center
Richard F. Riedel, MD
Associate Professor of Medicine with Tenure
Associate Director, Duke Sarcoma Center
Duke Cancer Institute
Duke University
ACKNOWLEDGEMENT
This activity is supported by an independent educational grant from SpringWorks Therapeutics, Inc.
DATE OF LIVE ACTIVITY
This activity was released on December 12, 2023 and is valid for 12 months. Requests for credit must be made no later than December 12, 2024.
TARGET AUDIENCE
The educational design of this activity addresses the needs of sarcoma specialists, medical oncologists, and other members of the care team for desmoid tumors.
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETE
This activity should take approximately 1 hour to complete.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.
DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPS
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
| Name of Faculty or Presenter | Reported Financial Relationship |
Mrinal Gounder, MD Associate Attending Professor Sarcoma Oncologist & Early Phase Drug Development Specialist Memorial Sloan Kettering Cancer Center | Consulting Fee (e.g., Advisory Board): Ayala Therapeutics, Aadi Biosciences, Rain Oncology, Epizyme, Regeneron, Boehringer Engelheim, Bayer Contracted Research (Principal Investigators must provide information, even if received by the institution): Ayala Therapeutics, Aadi Biosciences, Bayer, Boehringer Ingelheim, Epizyme, Springworks, Rain Oncology |
Richard F. Riedel, MD Associate Professor of Medicine with Tenure Associate Director, Duke Sarcoma Center Duke Cancer Institute Duke University | Consulting Fee (e.g., Advisory Board): AADi, Adaptimmune, Blueprint, Boehringer Ingelheim, Daiichi-Sankyo, Deciphera, GlaxoSmithKline, NanoCarrier, SpringWorks Contracted Research (Principal Investigators must provide information, even if received by the institution): AADi, AROG, Ayala, BioAtla, Blueprint, Cogent, Daiichi-Sankyo, Deciphera, GlaxoSmithKline, InhibRx, NanoCarrier, Oncternal, PTC Therapeutics, SARC, SpringWorks, Tracon, Trillium |
Christina Kosyla Vignette Participant Desmoid Tumor Patient | Nothing to disclose |
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT INFORMATION
Physician Accreditation Support:
For information about the physician accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.
Creators:
PeerView & the DTRF (Made possible with support from SpringWorks Therapeutics)
Availability:
Now through November 26, 2024
Mediums:
The PeerView inQuiry presentation can be downloaded in MP3 format, and the entire program is available as a podcast via the PeerView channels on Apple Podcasts, Spotify, TuneIn, Google Podcasts, and Amazon Alexa. The podcasts and online media player are fully compatible with all mobile devices. Furthermore, all the slides are easily downloadable as a PowerPoint slide kit.
Description:
Until recently, ICD-10-CM codes for desmoid tumors (DTs) were broadly defined, creating a significant impediment to research efforts. Through a didactic expert-led discussion, get to know the new ICD-10-CM codes for desmoid tumors and learn how to navigate these codes more efficiently as a healthcare provider or researcher in this new question-based activity that lets you earn your CME credit as you go.
This educational program leverages microlearning through question-based segments to help clinicians better navigate the variable presentations of desmoid tumors and the new ICD-10-CM codes. Throughout the program, two leading experts address gaps and barriers that affect healthcare providers, patients, and researchers by offering practical guidance on current evidence-based diagnostic strategies, describing the new desmoid tumor–specific ICD-10-CM codes, and detailing the new codes’ implications for clinical practice, patient care, and research. In addition to these question-based segments, downloadable Practice Aids and additional resources for clinicians and patients are available.
Upon completion of this activity, participants should be better able to:
- Discuss the gaps and barriers in the diagnosis and treatment of desmoid tumors (DTs), including the prior lack of DT-specific ICD-10-CM codes
- Characterize the details of the new DT-specific ICD-10-CM codes, including the subcategories for tumor locations
- Implement best practices for integrating the new DT-specific ICD-10-CM codes in clinical and research settings
- Employ the latest recommendations for establishing an accurate diagnosis and assigning the correct ICD-10-CM codes to patients with DTs to guide further care decisions
Past CME-certified programs on desmoid tumors:
Creators:
PeerView Institute for Medical Education (PVI) & the Desmoid Tumor Research Foundation (DTRF) (Made Possible with support from SpringWorks Therapeutics)
Availability:
Now through February 22, 2024.
Description:
Desmoid tumors are rare but aggressive soft-tissue tumors characterized by locally invasive growth, significant morbidity, and a high rate of recurrence. Considering that they are so rare, there are many challenges related to their recognition and establishment of an accurate diagnosis, and referral to a specialist is essential. Effective therapies have been lacking, but a number of systemic and local therapy options have been assessed in recent trials, with mixed results. Gamma secretase inhibitors are among the most recent promising, rational therapies for desmoid tumors that may transform the management of this disease. Given the transition of care from surgical approaches to more conservative strategies, the emergence of new systemic therapies, and the increasing importance of multidisciplinary coordination of care, there is an urgent need to address key questions and nuances related to modern treatment of patients with desmoid tumors.
This educational program comprises a series of short, focused educational modules that hone in on some of the key questions in the diagnosis and treatment of desmoid tumors. Experts provide an update on the evolving evidence base for new and emerging therapies, and offer practical, case-based guidance for the multidisciplinary care team to help facilitate the application of recent advances to practice with the goal of improving patient care and outcomes. Patient perspectives and experiences are also integrated into the activity to highlight the importance of their education and engagement in care decisions.
This PeerView program is chaired and presented by Ravin Ratan, MD, M.Ed from the MD Anderson Cancer Center. Dr. Ratan is joined on the faculty by Christina L. Roland, MD, MS, FACS, from MD Anderson Cancer Center and desmoid tumor patient, Kathleen Hodgkins.
Upon completion of this activity, participants should be better able to:
- Characterize the epidemiology, predisposing factors, molecular pathogenesis, and clinical characteristics of desmoid tumors
- Implement validated strategies that harness multidisciplinary team-based approaches for rapid recognition and accurate diagnosis of desmoid tumors
- Incorporate novel therapeutic approaches, including novel gamma-secretase inhibitors, into practice in the management of patients with desmoid tumors, taking into account the latest evidence, recommendations, and patient needs and preferences
Activity Release Date: November 30, 2022
Activity Expiration Date: December 29, 2023
Time to Complete Activity: 60 minutes
IMPORTANT NOTE: This activity expired on December 29, 203; credit is no longer available.
Activity Description
The management of patients with desmoid tumors is currently transitioning from surgical approaches to more conservative strategies by utilizing systemic therapy. The discovery that desmoid tumors are almost universally associated with genetic alterations in the Wnt/β-catenin pathway has provided rationale for the development of gamma secretase inhibitors (GSIs), a new promising class of agents, and several are in late-phase testing. Although no systemic therapies have received regulatory approval for the treatment of desmoid tumors to date, it is important to be prepared to learn how to integrate GSIs into practice.
This PeerView educational activity, based on a recent live symposium, features a panel of leading experts in managing patients with desmoid tumors. The faculty provide expert insights and practical guidance for navigating the latest treatment advances, including GSIs, for desmoid tumors. In addition, illustrative cases and clinical scenarios are discussed to demonstrate the emerging role and integration of novel GSIs in real-world patient care settings.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists, surgical oncologists, general surgeons, advanced practice clinicians, and other healthcare professionals involved in the care of patients with desmoid tumors.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe the epidemiology, predisposing factors, molecular pathogenesis, and clinical characteristics of adult and pediatric desmoid tumors
- Implement validated strategies that harness multidisciplinary team-based approaches to diagnose desmoid tumors, including referring patients to sarcoma specialists
- Integrate novel therapeutic approaches based on current evidence to include emerging therapies in the context of clinical trial enrollment into the treatment plans of patients with desmoid tumors
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Bernd Kasper, MD, PhD
Associate Professor
University of Heidelberg
Mannheim Cancer Center (MCC)
Sarcoma Unit
Mannheim, Germany
Bernd Kasper, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Ayala Pharmaceuticals; Bayer AG; Blueprint Medicines Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; PharmaMar; and SpringWorks Therapeutics.
Other Financial or Material Support as Chair of the EORTC Soft Tissue and Bone Sarcoma Group.
Faculty/Planner
Mrinal Gounder, MD
Associate Professor
Sarcoma Medical Oncology | Early Drug Development (Phase I)
MSK Physician Ambassador – India and Asia
Memorial Sloan Kettering Cancer Center
New York, New York
Mrinal Gounder, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Ayala Pharmaceuticals; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Epizyme; Karyopharm Therapeutics; Rain Therapeutics; SpringWorks Therapeutics; and TYME Inc.
Grant/Research Support from Ayala Pharmaceuticals; Bayer AG; Iterion Therapeutics; and SpringWorks Therapeutics.
Speakers Bureau participant with Amgen; Boehringer Ingelheim Pharmaceuticals, Inc.; and Karyopharm Therapeutics.
Faculty/Planner
Alessandro Gronchi, MD
Surgical Oncologist
Chair Sarcoma Service
Head of the Department of Surgery
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Alessandro Gronchi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bayer AG; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc; PharmaMar; and SpringWorks Therapeutics.
Grant/Research Support from Nanobiotix and PharmaMar.
Speakers Bureau participant with Deciphera Pharmaceuticals, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
 | In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Desmoid Tumor Research Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Support
This activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
About This CME Activity
PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.
Copyright © 2000-2022, PeerView
Continue Exploring
Clinicians & Researchers Newsletter
Receive monthly updates about treatment advances, grant applications, clinical trials, CME opportunities, and more.
The Annual DTRF International Desmoid Tumor Research Workshop
DTRF Patient Meeting
Our Patient Meeting is a time to hear from clinicians, researchers, and desmoid patients and caregivers during our annual DTRF Together We Will Weekend.
